<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159831</url>
  </required_header>
  <id_info>
    <org_study_id>LTI-01-2001</org_study_id>
    <nct_id>NCT04159831</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions</brief_title>
  <official_title>A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lung Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lung Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01
      (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining
      pleural effusions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of referral to surgery</measure>
    <time_frame>Post treatment (Day 4/Hospital discharge or at time of treatment failure)</time_frame>
    <description>Treatment failure, as evidenced by continued or worsening pleural sepsis and failure to adequately drain pleural effusion, resulting in referral to surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change in pleural opacity</measure>
    <time_frame>Post treatment (Day 4 or at time of treatment failure)</time_frame>
    <description>Change from baseline in absolute pleural opacity and relative change from baseline in pleural opacity volume assessed by chest CT at Day 4</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>400,000 U LTI-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400,000 U LTI-01 qd x 3 days administered intrapleurally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800,000 U LTI-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800,000 U LTI-01 qd x 3 days administered intrapleurally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1,200,000 U LTI-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,200,000 U LTI-01 qd x 3 days administered intrapleurally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (normal saline) 6ml qd x 3 days administered intrapleurally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTI-01</intervention_name>
    <description>single-chain urokinase plasminogen activator, scuPA</description>
    <arm_group_label>1,200,000 U LTI-01</arm_group_label>
    <arm_group_label>400,000 U LTI-01</arm_group_label>
    <arm_group_label>800,000 U LTI-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female ≥ 18 years of age who provide written informed consent

          -  Clinical presentation compatible with complicated parapneumonic pleural effusion
             (CPE), empyema or other type of pleural infection

          -  Has pleural fluid requiring drainage as determined by chest ultrasonography or by
             chest CT, and which is either:

          -  a) purulent; b) gram stain positive; c) culture positive; d) pH &lt; 7.2; or e) glucose &lt;
             60 mg/dL (3.3 mmol/L)

          -  Failure to adequately drain pleural fluid ≥ 3 hours post insertion of patent chest
             tube within the pleural space, as evidenced by one or more of the following criteria:

          -  &gt; 2 cm depth of fluid by ultrasound or CT

          -  &lt; 80% drainage from chest radiograph obtained prior to chest tube insertion.

        Key Exclusion Criteria:

          -  Current pleural infection already treated with intrapleural fibrinolytic therapy

          -  Evidence of ipsilateral fibrothorax (e.g. CT scan with &gt; 0.5 cm visceral pleural
             thickening)

          -  History of multiple thoracenteses or thoracic surgical procedures within 3 months of
             screening

          -  Previous pneumonectomy on the side of the pleural effusion

          -  Current bilateral pleural infections

          -  Known non-expandable lung prior to this pleural infection

          -  Known or high clinical suspicion of a malignant pleural effusion

          -  Existing indwelling or tunneled pleural catheter

          -  Current infected hepatic hydrothorax or evidence of another abdominal process (e.g.
             pancreatic cyst or renal cyst) communicating with the pleural space

          -  Active bleeding, or any condition in which bleeding is either a significant risk or
             would be difficult to manage

          -  Fully anticoagulated patients on heparin, warfarin or novel oral anti-coagulants who
             are not able to temporarily discontinue anti-coagulants while receiving study
             medication and for 2 days after last dose of study medication Note: patients receiving
             low-molecular weight heparin for immobilization or anti-platelet agents are not
             excluded.

          -  Presence of severe metabolic derangements that would interfere with study assessments

          -  Systolic blood pressure &gt;185 mmHg or diastolic blood pressure &gt; 110 mmHg at screening

          -  Hemodynamically unstable and/or requires use of intravenous vasopressor therapy

          -  Expected survival &lt; 3 months from a pathology other than the qualifying infected,
             non-draining pleural effusion (e.g. metastatic lung carcinoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Emery, MPSH</last_name>
    <phone>303-902-6308</phone>
    <email>lemery@lungtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Kinney, MSPH</last_name>
    <phone>720-470-4743</phone>
    <email>akinney@lungtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Stumph</last_name>
      <phone>303-724-6052</phone>
    </contact>
    <investigator>
      <last_name>Ali Musani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zubaida Dabre</last_name>
      <phone>203-737-5403</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Puchalski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Los</last_name>
      <phone>410-955-5288</phone>
    </contact>
    <investigator>
      <last_name>Lonny Yarmus, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erick Flores</last_name>
      <phone>781-475-8916</phone>
    </contact>
    <investigator>
      <last_name>Fayez Kheir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital and Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce Pelletier</last_name>
      <phone>781-744-3706</phone>
    </contact>
    <investigator>
      <last_name>Carla Lamb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Delgado, BS</last_name>
      <phone>919-349-0496</phone>
    </contact>
    <investigator>
      <last_name>Jason Akulian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Coles</last_name>
      <phone>919-668-3812</phone>
    </contact>
    <investigator>
      <last_name>Momen M Wahidi, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamaal Saleh, BS</last_name>
      <phone>614-366-2258</phone>
    </contact>
    <investigator>
      <last_name>Jasleen Pannu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Andronov</last_name>
      <phone>215-349-8726</phone>
    </contact>
    <investigator>
      <last_name>Kevin C Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lance Roller</last_name>
      <phone>615-875-7313</phone>
    </contact>
    <investigator>
      <last_name>Fabien Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adetoun Sodimu, MPH, MBA</last_name>
      <phone>214-645-6493</phone>
    </contact>
    <investigator>
      <last_name>Muhanned Abu-Hijleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Weaver</last_name>
      <phone>801-587-7855</phone>
    </contact>
    <investigator>
      <last_name>Sikandar Ansari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INOVA</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serina Zorrilla</last_name>
      <phone>703-776-3757</phone>
    </contact>
    <investigator>
      <last_name>Amit Mahajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Frayser</last_name>
      <phone>804-828-7966</phone>
    </contact>
    <investigator>
      <last_name>Samira Shojaee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

